Skip to main content
OpenTrials
Completed

NCT Number: NCT00373568

Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis

Miltefosine (longer course) will be used to try to improve the cure rate of mucosal leishmaniasis

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Leishmaniasis Euglenozoa Infections Infections Parasitic Diseases Protozoan Infections Skin Diseases Skin Diseases, Infectious Skin Diseases, Parasitic Skin and Connective Tissue Diseases Vector Borne Diseases

Age range

12 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Palos Blancos

Palos Blancos, Bolivia

About this study

Miltefosine (42 days) will be used to try to improve upon the cure rate with 28 days of drug for bolivian mucosal leishmaniasisi

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Mucosal leishmaniasis

Exclusion criteria

  • No comcomitant disease as judged by laboratory and clinical parameters

Treatment and study plan

miltefosine: 2.5 mg/kg/day for 42 days

Drug

Primary outcomes

  1. efficacy

Secondary outcomes

  1. safety

Sponsors and collaborators

Lead sponsor

AB Foundation

Other

Registry information

Official study title

Miltefosine (42 Days) for Mucosal Leishmaniasisi

Important dates

Study start
2005
Study completion
2007
First posted
Sep 8, 2006
Registry last updated
Jun 2, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.